What's Happening?
Duopharma Biotech Berhad has reported a 14.5% increase in revenue for FY2025, reaching RM931.69 million. The company attributes this growth to strong demand across all business segments and a surge in insulin supply. Duopharma is focusing on expanding
its portfolio to include treatments for non-communicable and chronic conditions, and has introduced new consumer healthcare products. The company has also achieved a milestone by obtaining Halal certification for its biologic product, an erythropoietin biosimilar. Duopharma remains a key supplier to Malaysia's Ministry of Health, with contracts to supply various pharmaceutical products.
Why It's Important?
Duopharma's growth and strategic initiatives are significant for Malaysia's pharmaceutical industry, particularly in enhancing national self-reliance in medicine supply. By expanding its product portfolio and manufacturing capacity, Duopharma is aligning with national policies aimed at boosting domestic pharmaceutical production. This not only supports Malaysia's healthcare ecosystem but also positions Duopharma as a leader in the regional market. The company's focus on Halal-certified products further differentiates it in the global pharmaceutical landscape.
What's Next?
Duopharma plans to continue expanding its product offerings and manufacturing capabilities, in line with Malaysia's New Industrial Master Plan 2030. The company is also set to supply Insulin Aspart to the Ministry of Health from 2026 to 2028. With ongoing investments in innovation and partnerships, Duopharma aims to strengthen its market position and support Malaysia's goal of pharmaceutical self-reliance.
